{"id":28350,"date":"2025-02-28T22:05:54","date_gmt":"2025-02-28T14:05:54","guid":{"rendered":"https:\/\/flcube.com\/?page_id=28350"},"modified":"2025-03-15T12:46:06","modified_gmt":"2025-03-15T04:46:06","slug":"jan-2024-fineline-deals-book","status":"publish","type":"page","link":"https:\/\/flcube.com\/?page_id=28350","title":{"rendered":"Jan. 2025 Fineline Deals Book"},"content":{"rendered":"\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>China Pharmaceutical BD Transaction Review &#8211; Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. &#8211; Fineline Deals Book Jan. 2025<\/p>\n<\/blockquote>\n\n\n\n<p class=\"is-style-info\">According to incomplete statistics from Fineline Info &amp; Tech, there were a total of <strong>24<\/strong> pharmaceutical BD and M&amp;A transactions in China in Jan 2025, including <strong>1<\/strong> cross-border asset acquisitions, <strong>18<\/strong> outbound transactions, and <strong>5<\/strong> domestic transactions.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"193\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" src=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-1024x193.png\" alt=\"Fineline Info &amp; Tech\" class=\"wp-image-13755\" srcset=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-1024x193.png 1024w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-300x57.png 300w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-768x145.png 768w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-610x115.png 610w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png 1214w\" \/><\/figure>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/Jan.-2025-Fineline-Deals-Book.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Jan. 2025 Fineline Deals Book.\"><\/object><a id=\"wp-block-file--media-00c9b5b1-022c-4727-9bf8-dbb591b16078\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/Jan.-2025-Fineline-Deals-Book.pdf\">Jan. 2025 Fineline Deals Book<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/Jan.-2025-Fineline-Deals-Book.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-00c9b5b1-022c-4727-9bf8-dbb591b16078\">Download<\/a><\/div>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n\n\n<h4 class=\"wp-block-heading\" id=\"h-cross-border-license-in\">Cross-border License In<\/h4>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n<p class=\"has-text-align-left\"><a href=\"https:\/\/flcube.com\/?p=21111\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=21111\">China Medical System Licenses Alpha Cognition\u2019s Zunveyl for Dementia Treatment in Asia<\/a><\/strong><\/p>\n\n\n\n<p>China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition Inc., obtaining development, regulatory filing, manufacturing, import, export, and commercialization rights to the Canadian firm\u2019s Zunveyl (benzgalantamine delayed-release tablets). The drug targets mild to moderate dementia of Alzheimer\u2019s disease (AD) and is approved for the\u2026 [<a href=\"https:\/\/flcube.com\/?p=21111\">Full Artical<\/a>]<\/p>\n\n\n\n<p><\/p>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n\n\n<h4 class=\"wp-block-heading\" id=\"h-cross-border-license-out\">Cross-border License Out<\/h4>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=20433\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=20433\">Innovent Biologics Strikes Licensing Deal with Roche for IBI3009 ADC<\/a><\/strong><\/p>\n\n\n\n<p>China-based Innovent Biologics, Inc. (HKG: 1801) has announced a significant licensing agreement with Swiss pharmaceutical giant Roche (SWX: ROG). The agreement grants Roche global exclusive development, manufacturing, and commercialization rights to Innovent\u2019s IBI3009, a DLL3-targeted antibody drug conjugate (ADC) that is anticipated to offer new treatment options for patients with\u2026 [<a href=\"https:\/\/flcube.com\/?p=20433\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=20440\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=20440\">Sino Biopharmaceutical\u2019s Chia Tai Tianqing Secures Exclusive Promotion Rights for Naldemedine in China<\/a><\/strong><\/p>\n\n\n\n<p>China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced an exclusive market promotion agreement between its subsidiary Chia Tai Tianqing and Ping An-Shionogi Co., Ltd, a joint venture between China-based commercial insurance firm Ping An Insurance (Group) Ltd and Japanese pharmaceutical firm Shionogi &amp; Co., Ltd. Under this initially 11-year accord,\u2026[<a href=\"https:\/\/flcube.com\/?p=20440\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28361\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28361\">Duality Biologics and Avenzo Ink Exclusive License for DB-1418\/AVZO-1418<\/a><\/strong><\/p>\n\n\n\n<p>On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced that they have entered into an exclusive license agreement. Under the agreement, Avenzo will obtain exclusive rights to develop, manufacture, and commercialize DB-1418\/AVZO-1418 globally, excluding Greater China. DB-1418\/AVZO-1418 is an EGFR\/HER3 bispecific antibody-drug conjugate (ADC)\u2026[<a href=\"https:\/\/flcube.com\/?p=28361\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21218\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=21218\">Biocytogen and SOTIO Biotech Partner on Colorectal Cancer ADC Candidate SOT109<\/a><\/strong><\/p>\n\n\n\n<p>China-based Biocytogen (HKG: 2315) has announced an option and licensing agreement with SOTIO Biotech, allowing the Czech Republic firm to use its tumor-targeted fully human antibodies to develop SOT109, SOTIO\u2019s new antibody drug conjugate (ADC) candidate. The ADC is intended for the treatment of colorectal cancer and other gastrointestinal (GI)\u2026 [<a href=\"https:\/\/flcube.com\/?p=21218\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21064\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=21064\">Xtalpi\u2019s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery<\/a><\/strong><\/p>\n\n\n\n<p>Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB), granting the Belgian biopharma commercial rights to utilize Ailux\u2019s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were\u2026[<a href=\"https:\/\/flcube.com\/?p=21064\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28338\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28338\">SciWind Bio and Verdiva Bio Partner on Global Development of Obesity Therapies<\/a><\/strong><\/p>\n\n\n\n<p>On January 10, SciWind Bio announced a global development and commercialization license and collaboration agreement with Verdiva Bio, excluding Greater China and South Korea. Verdiva Bio is a clinical \u2013 stage global biopharmaceutical company focused on developing innovative therapies for obesity and other cardiovascular metabolic disorders. Collaboration DetailsThe collaboration includes\u2026 [<a href=\"https:\/\/flcube.com\/?p=28338\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21221\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=21221\">Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development<\/a><\/strong><\/p>\n\n\n\n<p>China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm Timberlyne Therapeutics, Inc., granting the startup biopharma exclusive development, manufacturing, and commercialization rights to its CM313, a CD38-targeted monoclonal antibody (mAb). The agreement covers global rights, excluding mainland China, Hong Kong, Macau, and Taiwan. Financial\u2026 [<a href=\"https:\/\/flcube.com\/?p=21221\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28371\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28371\">Zai Lab and MediLink Therapeutics Partner to Develop LRRC15 ADC Drug ZL-6201 for Solid Tumors<\/a><\/strong><\/p>\n\n\n\n<p>On January 10, Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced a new strategic cooperation and global licensing agreement with MediLink Therapeutics. The partnership aims to utilize MediLink\u2019s TMALIN\u00ae antibody-drug conjugate (ADC) platform to develop a novel LRRC15 ADC drug, ZL-6201, targeting solid tumors. The antibody for this product was\u2026[<a href=\"https:\/\/flcube.com\/?p=28371\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21482\"><strong><br>Simcere Zaiming and AbbVie Ink $1.055B License Deal for MM Drug SIM0500<\/strong><\/a><\/p>\n\n\n\n<p>China-based Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced a significant strategic move through its oncology subsidiary, Simcere Zaiming. The company has entered into a license option agreement with global pharmaceutical giant AbbVie Inc. (NYSE: ABBV) for the development of its promising drug candidate, SIM0500. Deal Structure and FinancialsUnder the\u2026 [<a href=\"https:\/\/flcube.com\/?p=21482\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21495\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=21495\">Zhaoke Ophthalmology Partners with AFT for Brimochol PF Distribution in ANZ<\/a><\/strong><\/p>\n\n\n\n<p>China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a strategic distribution and supply agreement with New Zealand-headquartered AFT Pharmaceuticals Limited, a leading healthcare product manufacturer and distributor. The agreement pertains to Brimochol PF, a fixed dose of carbachol and bromonidine tartrate that is preservative free, co-developed by Tenpoint Therapeutics Ltd.\u2026[<a href=\"https:\/\/flcube.com\/?p=21495\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21560\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=21560\">Henlius and Abbott Sign License Agreement for Biosimilars and Biologic Drug<\/a><\/strong><\/p>\n\n\n\n<p>China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced a strategic license agreement with Abbott Laboratories (NYSE: ABT). The agreement grants the US multinational company exclusive or semi-exclusive development and commercialization rights to four biosimilars and one novel biologic drug in 69 emerging countries and regions. The deal, for which\u2026 [<a href=\"https:\/\/flcube.com\/?p=21560\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28373\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28373\">Bio-Thera Solutions Licenses BAT2206 to World Medicine for Turkey<\/a><\/strong><\/p>\n\n\n\n<p>On January 16, Bio-Thera Solutions Ltd (SHA: 688177), a science \u2013 driven innovative global biopharmaceutical company based in Guangzhou, China, announced that it has recently signed a licensing and commercialization agreement with World Medicine for BAT2206. BAT2206 is a biosimilar developed based on Stelara\u00ae (ustekinumab). Agreement DetailsUnder the agreement, World\u2026 [<a href=\"https:\/\/flcube.com\/?p=28373\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=22392\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=22392\">Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium<\/a><\/strong><\/p>\n\n\n\n<p>China-based Keymed Biosciences Inc. (HKG: 2162) and InnoCare Pharma (HKG: 9969, SHA: 688428) have jointly announced a licensing agreement with Prolium, a US-based biotech backed by RTW Investments. Under the terms of the agreement, Prolium will obtain development, regulatory filing, manufacturing, and commercialization rights to ICP-B02 (CM355), a CD20xCD3 bispecific\u2026[<a href=\"https:\/\/flcube.com\/?p=22392\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=22383\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=22383\">Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets<\/a><\/strong><\/p>\n\n\n\n<p>China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement with Denmark-based LEO Pharma A\/S, granting the dermatology specialist exclusive rights to store, distribute, promote, market, and sell its PD-1 inhibitor, toripalimab, in the European Union (EU), the European Economic Area (EEA), Switzerland, and the\u2026 [<a href=\"https:\/\/flcube.com\/?p=22383\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=22561\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=22561\">Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent<\/a><\/strong><\/p>\n\n\n\n<p>Lepu Biopharma Co., Ltd (HKG: 2157) has announced an exclusive licensing agreement with ArriVent BioPharma, Inc. (NASDAQ: AVBP) for MRG007, a potential best-in-class antibody-drug conjugate (ADC) targeting gastrointestinal (GI) cancers. This partnership aims to advance the development and commercialization of MRG007 globally, excluding Greater China. Agreement DetailsUnder the terms of\u2026 [<a href=\"https:\/\/flcube.com\/?p=22561\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=23134\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=23134\">GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development<\/a><\/strong><\/p>\n\n\n\n<p>Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth USD 13 billion with US \u2013 based Biohaven Pharmaceutical (NYSE: BHVN) and South Korean biotech Aimed Bio Inc. The agreements coincide with the global launch of GeneQuantum\u2019s IDiscovery, an intelligent automated development system for bioconjugated\u2026[<a href=\"https:\/\/flcube.com\/?p=23134\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28341\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28341\">CStone Pharmaceuticals Partners with SteinCares for Sugemalimab Commercialization in Latin America<\/a><\/strong><\/p>\n\n\n\n<p>CStone Pharmaceuticals (HKG: 2616), a China \u2013 based biopharmaceutical company focused on oncology drug development, announced on January 27 a strategic commercialization partnership with SteinCares, a leading pharmaceutical company in the Latin American market. Under the licensing and commercialization agreement, SteinCares will obtain the rights to commercialize sugemalimab in 10\u2026 [<a href=\"https:\/\/flcube.com\/?p=28341\">Full Artical<\/a>]<\/p>\n\n\n\n<p><\/p>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n\n\n<h4 class=\"wp-block-heading\" id=\"h-domestic-transactions-in-china\">Domestic Transactions in China<\/h4>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=20562\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=20562\">Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau<\/a><\/strong><\/p>\n\n\n\n<p>China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese firm Shandong Boan Biotechnology Co., Ltd (HKG: 6955). The partnership aims to promote the marketing and sales of Shandong Boan\u2019s biosimilars BA6101 and BA1102 in Hong Kong and Macau. BA6101 is a biosimilar version of\u2026 [<a href=\"https:\/\/flcube.com\/?p=20562\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28345\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28345\">Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co. Launch Strategic Partnership for Linagliptin<\/a><\/strong><\/p>\n\n\n\n<p>On January 7, Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) held a strategic cooperation launch ceremony, announcing a partnership on the national retail market for Outangning\u00ae (Linagliptin). Starting from January 1, 2025, the distribution and promotion of Linagliptin in non \u2013 medical institution\u2026 [<a href=\"https:\/\/flcube.com\/?p=28345\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21475\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=21475\">3SBio Acquires Licensing Rights to Duality Biologics\u2019 HER2-Targeting ADC DB-1303<\/a><\/strong><\/p>\n\n\n\n<p>China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a leading antibody conjugate drug (ADC) developer with operations in the United States and China. The collaboration centers on the licensing rights to Duality Biologics\u2019 promising ADC, DB-1303, which targets the HER2 protein. Agreement DetailsPursuant to\u2026[<a href=\"https:\/\/flcube.com\/?p=21475\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21789\"><strong><\/strong><\/a><strong><a href=\"https:\/\/flcube.com\/?p=21789\">Simcere Licenses Fermion\u2019s AI-Enabled Painkiller FZ002-037<\/a><\/strong><\/p>\n\n\n\n<p>China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced a licensing agreement with compatriot firm Fermion, an artificial intelligence (AI) empowered small-molecule drug developer, relating to an investigational SSTR4-targeted painkiller candidate drug, FZ002-037. This strategic partnership aims to advance the development and commercialization of FZ002-037 in Greater China, including mainland\u2026 [<a href=\"https:\/\/flcube.com\/?p=21789\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=23114\"><strong><br>China Medical System Partners with MabGeek for Innovative Drug MG-K10<\/strong><\/a><\/p>\n\n\n\n<p>China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek Biotechnology Co., Ltd., a fellow Chinese biotech firm, for the latter\u2019s Category 1 drug MG-K10. This marks CMS\u2019s second major licensing deal in less than a month. Financial details of the agreement were not disclosed.\u2026 [<a href=\"https:\/\/flcube.com\/?p=23114\">Full Artical<\/a>]<\/p>\n\n\n\n<p><\/p>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n\n\n<h4 class=\"wp-block-heading\" id=\"h-monthly-roundup\">Monthly Roundup<\/h4>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n<p><strong>Key Insights:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cross-Border Licensing Dominates:<\/strong> China\u2019s pharmaceutical sector witnessed a flurry of cross-border licensing deals in January 2025, with 19 out of 24 transactions involving international partnerships. The trend underscores Chinese biotech firms\u2019 growing ambition to commercialize assets globally, particularly in the U.S. and EU markets.<\/li>\n\n\n\n<li><strong>Biosimilars and Biologics Drive Activity:<\/strong> Deals involving biosimilars, bi-specific antibodies, and antibody-drug conjugates (ADCs) were prominent, reflecting global demand for cost-effective therapies and innovative oncology treatments.<\/li>\n\n\n\n<li><strong>Financial Windfalls:<\/strong> Milestone payments and upfront fees highlight the sector\u2019s attractiveness. Notable deals include MoonBiotech\u2019s $1.05B agreement with AbbVie for SIM0400 and SciWind Bio\u2019s $2.4B partnership with Verdiva Bio for amylin receptor agonists.<\/li>\n\n\n\n<li><strong>Domestic Consolidation:<\/strong> Local players like Boehringer Ingelheim and Duality Biotherapeutics also engaged in strategic domestic deals, signaling efforts to strengthen China\u2019s internal pharma ecosystem.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Deal Highlights<\/strong><\/h3>\n\n\n\n<p><strong>MoonBiotech\u2019s Blockbuster Deal<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transaction:<\/strong> Out-licensed SIM0400 (NMPA Phase I) to AbbVie for $1.05B, marking one of January\u2019s largest biotech deals.<\/li>\n\n\n\n<li><strong>Implications:<\/strong> Validates China\u2019s R&amp;D capabilities in early-stage oncology assets. AbbVie\u2019s involvement suggests confidence in SIM0400\u2019s potential for global markets.<\/li>\n<\/ul>\n\n\n\n<p><strong>SciWind Bio\u2019s Amylin Franchise<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transaction:<\/strong> Licensed oral and subcutaneous amylin receptor agonists to Verdiva Bio for $2.4B, including a $70M upfront payment.<\/li>\n\n\n\n<li><strong>Analysis:<\/strong> Reflects rising interest in metabolic disease therapies, with amylin agonists targeting obesity and diabetes.<\/li>\n<\/ul>\n\n\n\n<p><strong>Bio-Thera Solutions\u2019 Global Push<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transaction:<\/strong> Secured FDA and NMPA market approval filings for BAT2206 (a biosimilar) with World Medicine.<\/li>\n\n\n\n<li><strong>Takeaway:<\/strong> Biosimilars remain a key export focus for Chinese firms, leveraging regulatory pathways to penetrate Western markets.<\/li>\n<\/ul>\n\n\n\n<p><strong>KeyMedBio\u2019s CM313 Deal<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transaction:<\/strong> Licensed CM313 (oral amylin receptor agonist) to Timberlyne for $367.5M in milestones.<\/li>\n\n\n\n<li><strong>Context:<\/strong> Preclinical assets like CM313 attract partners seeking first-in-class therapies for chronic diseases.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Strategic Implications<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Ambitions:<\/strong> Chinese biotechs are prioritizing cross-border partnerships to accelerate commercialization and reduce R&amp;D costs. Deals with Roche, UCB, and AbbVie signal a shift from domestic focus to global competitiveness.<\/li>\n\n\n\n<li><strong>Regulatory Synergy:<\/strong> NMPA and FDA Phase III approvals (e.g., Zai Lab\u2019s TMALIN) highlight alignment with international standards, easing market entry barriers.<\/li>\n\n\n\n<li><strong>Investor Outlook:<\/strong> High milestone payments (e.g., MoonBiotech\u2019s $1.05B) underscore the sector\u2019s potential for returns, attracting capital to early-stage assets.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Guidance for Investors and Stakeholders<\/strong><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Focus on Biosimilars and Biologics:<\/strong> These categories dominate deal flow, with AbbVie and Bio-Thera Solutions leading the charge. Monitor FDA\/NMPA filings for market entry timelines.<\/li>\n\n\n\n<li><strong>Preclinical Assets:<\/strong> Early-stage deals (e.g., KeyMedBio\u2019s CM313) offer high-risk, high-reward opportunities. Evaluate partners\u2019 clinical trial track records.<\/li>\n\n\n\n<li><strong>Domestic Dynamics:<\/strong> Local consolidation (e.g., Boehringer Ingelheim\u2019s Linagliptin deal) suggests China\u2019s pharma ecosystem is maturing, with M&amp;A activity likely to rise.<\/li>\n<\/ol>\n\n\n\n<p><strong>Next Steps:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Track FDA\/NMPA approval timelines for key assets (e.g., MoonBiotech\u2019s SIM0400, Bio-Thera\u2019s BAT2206).<\/li>\n\n\n\n<li>Assess partners\u2019 commercialization capabilities in target markets (e.g., AbbVie\u2019s oncology pipeline).<\/li>\n\n\n\n<li>Monitor domestic M&amp;A for potential undervalued opportunities in China\u2019s biotech space.<\/li>\n<\/ul>\n\n\n\n<p><em>For more insights, follow <a href=\"https:\/\/flcube.com\">Fineline Info &amp; Tech<\/a><\/em><\/p>\n\n\n\n<p><strong>Previous Recommendations<\/strong><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=21585\">Dec. 2024 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=16824\">Nov. 2024 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China Pharmaceutical BD Transaction Review &#8211; Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","footnotes":""},"class_list":["post-28350","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jan. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?page_id=28350\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jan. 2025 Fineline Deals Book\" \/>\n<meta property=\"og:description\" content=\"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?page_id=28350\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-15T04:46:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1214\" \/>\n\t<meta property=\"og:image:height\" content=\"229\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=28350\",\"url\":\"https:\\\/\\\/flcube.com\\\/?page_id=28350\",\"name\":\"Jan. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=28350#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=28350#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/38-02-1024x193.png\",\"datePublished\":\"2025-02-28T14:05:54+00:00\",\"dateModified\":\"2025-03-15T04:46:06+00:00\",\"description\":\"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=28350#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?page_id=28350\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=28350#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/38-02.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/38-02.png\",\"width\":1214,\"height\":229,\"caption\":\"Fineline Info & Tech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=28350#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jan. 2025 Fineline Deals Book\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jan. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry","description":"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?page_id=28350","og_locale":"en_US","og_type":"article","og_title":"Jan. 2025 Fineline Deals Book","og_description":"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book","og_url":"https:\/\/flcube.com\/?page_id=28350","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_modified_time":"2025-03-15T04:46:06+00:00","og_image":[{"width":1214,"height":229,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/flcube.com\/?page_id=28350","url":"https:\/\/flcube.com\/?page_id=28350","name":"Jan. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?page_id=28350#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?page_id=28350#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-1024x193.png","datePublished":"2025-02-28T14:05:54+00:00","dateModified":"2025-03-15T04:46:06+00:00","description":"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book","breadcrumb":{"@id":"https:\/\/flcube.com\/?page_id=28350#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?page_id=28350"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?page_id=28350#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png","width":1214,"height":229,"caption":"Fineline Info & Tech"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?page_id=28350#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jan. 2025 Fineline Deals Book"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages\/28350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28350"}],"version-history":[{"count":9,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages\/28350\/revisions"}],"predecessor-version":[{"id":29316,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages\/28350\/revisions\/29316"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}